Similar Search Results

Cost-Effectiveness Analysis of Extended-Release Formulations of Oxybutynin and Tolterodine for the Management of Urge Incontinence

Hughes, Dyfrig A.; Dubois, Dominique - In: PharmacoEconomics 22 (2004) 16, pp. 1047-1059

Introduction: Oxybutynin and tolterodine are two drugs widely used for the management of overactive bladder and urge … cost effectiveness of oxybutynin extended-release (Oxy-XL), tolterodine extended-release (Tol-ER), tolterodine immediate …, their costs, compared with generic immediate-release (IR) oxybutynin, are significantly greater. This study compared the …

Persistent link: https://www.econbiz.de/10005449218

Corrigendum

Adis International Limited - In: PharmacoEconomics 30 (2012) 6, pp. 534-535

Persistent link: https://www.econbiz.de/10010548288

Management of Overactive Bladder: Defining the Role of Extended-Release Tolterodine

Keam, Susan J.; Perry, Caroline M. - In: Disease Management and Health Outcomes 12 (2004) 2, pp. 121-142

-release oxybutynin. The incidence of dry mouth with extended-release tolterodine or transdermal oxybutynin is similar. In economic models …-release tolterodine or immediate-release oxybutynin, and is as cost effective as extended-release oxybutynin. In conclusion, clinical and … efficacy and tolerability (including dry mouth) to transdermal oxybutynin. Extended-release tolterodine is, therefore, a …

Persistent link: https://www.econbiz.de/10005404696

Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease: A Review of the Evidence and Methodological Issues

Rutten-van Molken, Maureen P.M.H. Rutten-van Mlken; … - In: PharmacoEconomics 30 (2012) 4, pp. 271-302

Background:Background: Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number of disease-year equivalents and deaths attributable to COPD are high. Guidelines for the pharmacological treatment of the disease recommend an individualized step-up approach in...

Persistent link: https://www.econbiz.de/10009653280

Aggressive Non-Hodgkin

Beard, Stephen M.; Wall, Lucy; Gaffney, Louise; … - In: PharmacoEconomics 22 (2004) 4, pp. 207-224

High-intermediate grade non-Hodgkin Despite a significant rise in the incidence of NHL over recent years, there remains only limited published economic study concerning the overall lifetime cost of treatment, the cost effectiveness of specific treatments or the overall societal cost burden of...

Persistent link: https://www.econbiz.de/10005243182

Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

Zeliadt, Steven B.; Penson, David F. - In: PharmacoEconomics 25 (2007) 4, pp. 309-327

The resources devoted to managing metastatic prostate cancer are enormous, yet little attention has been given to directly measuring the economic consequences of treatment alternatives. The purpose of this article was to evaluate the pharmacoeconomics of available treatments for metastatic...

Persistent link: https://www.econbiz.de/10005243192

Cost Considerations in the Treatment of Colorectal Cancer

Jansman, Frank G.A.; Postma, Maarten J.; Brouwers, … - In: PharmacoEconomics 25 (2007) 7, pp. 537-562

Colorectal cancer is among the most common malignancies in developed countries. Screening can reduce mortality significantly, although the most appropriate method is still under debate. Observational studies have revealed that lifestyle measures may also be beneficial for prevention of...

Persistent link: https://www.econbiz.de/10005243196

Economic Burden of Renal Cell Carcinoma: Part I - An Updated Review

Shih, Ya-Chen T.; Chien, Chun-Ru; Xu, Ying; Pan, I-Wen; … - In: PharmacoEconomics 29 (2011) 4, pp. 315-329

The economic burden of renal cell carcinoma (RCC) came into sharp focus when the UK National Institute for Health and Clinical Excellence (NICE) denied coverage (later reversed) of sunitinib for metastatic RCC. In the first of two articles that provide updated reviews and analyses of the...

Persistent link: https://www.econbiz.de/10010614347

Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations

Nyman, John A.; Jalal, Hawre J. - In: PharmacoEconomics 29 (2011) 3, pp. 173-174

Persistent link: https://www.econbiz.de/10010614369

Cost-Effectiveness Analysis in Markets with High Fixed Costs

Cutler, David M.; Ericson, Keith M. Marzilli. - In: PharmacoEconomics 28 (2010) 10, pp. 867-875

We consider how to conduct cost-effectiveness analysis when the social cost of a resource differs from the posted price. From the social perspective, the true cost of a medical intervention is the marginal cost of delivering another unit of a treatment, plus the social cost (deadweight loss) of...

Persistent link: https://www.econbiz.de/10008519890

1
2
3
4
5
6
7
8
9
10
Next
Last